Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the consistency evaluation application of the generic drug, Buprenorphine Hydrochloride Tablets [1] Group 1 - The drug Buprenorphine is the first non-benzodiazepine anxiolytic, acting as a 5-HT1A receptor agonist [1] - It selectively binds to the brain's 5-HT1A receptors, reducing excessive 5-HT activity associated with anxiety disorders [1] - The clinical advantage of this drug is its lack of dependency and withdrawal reactions, indicating a higher safety profile [1]

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets [1] Group 1: Company Developments - Beijing Huasu has received the acceptance notice for the application of Buprenorphine Hydrochloride Tablets (specifications: 5mg, 10mg) [1] - The drug Buprenorphine is the first non-benzodiazepine anxiolytic, acting as a 5-HT1A receptor agonist [1] Group 2: Drug Characteristics - Buprenorphine works by selectively binding to the brain's 5-HT1A receptors, reducing excessive 5-HT activity associated with anxiety disorders [1] - The main clinical advantage of Buprenorphine is its lack of drug dependence and withdrawal reactions, indicating a higher safety profile [1] - The indications for Buprenorphine Hydrochloride Tablets include various anxiety disorders [1]

截至发稿，中关村市值为37亿元。 每经AI快讯，中关村（SZ 000931，收盘价：4.96元）12月19日晚间发布公告称，近日，北京中关村科 技发展（控股）股份有限公司下属公司北京华素制药股份有限公司取得国家知识产权局颁发的发明专利 证书。专利名称为"一种盐酸丁螺环酮的制备方法"。 2025年1至6月份，中关村的营业收入构成为：生物医药占比80.15%，混凝土占比13.22%，养老健康占 比4.12%，其他占比2.51%。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 曾健辉） ...

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets [1] Group 1: Company Developments - Beijing Huasu has received the acceptance notice for the consistency evaluation of Buprenorphine Hydrochloride Tablets in 5mg and 10mg specifications [1] - Buprenorphine is the first non-benzodiazepine anxiolytic drug, acting as a 5-HT1A receptor agonist to reduce excessive 5-HT activity in anxiety disorders [1] Group 2: Product Characteristics - The clinical advantage of Buprenorphine is its lack of drug dependence and withdrawal reactions, indicating a higher safety profile [1] - The indications for Buprenorphine Hydrochloride Tablets include various anxiety disorders [1]

关于下属公司北京华素盐酸丁螺环酮片一致性评价申报收到国家药品监督管理局《受理通知书》的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-141 北京中关村科技发展（控股）股份有限公司 关于下属公司北京华素盐酸丁螺环酮片一致性评价申报收到 药品名称：盐酸丁螺环酮片 注册商标：苏新® 剂型：片剂 规格：5mg、10mg 申请事项：境内生产药品一致性评价 申请人：北京华素制药股份有限公司 国家药品监督管理局《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属公司 北京华素制药股份有限公司（以下简称：北京华素）于近日收到国家药品监督 管理局（以下简称：国家药监局）签发的《受理通知书》，盐酸丁螺环酮片（规 格：5mg、10mg）仿制药一致性评价申请获得受理，现将相关情况公告如下： 一、基本信息 北京华素的盐酸丁螺环酮片仿制药一致性评价申请获得国家药监局的受理， 标志着该品种一致性评价工作进入审评阶段，公司将积极推进后续相关工作， 如顺利获批将增加企业和市场竞争力， ...

关于下属公司北京华素取得发明专利证书的公告 共 1 页 注：专利权自授权公告之日起生效。专利权期限为二十年，自申请日起算。 上述发明专利不会对公司近期生产经营产生重大影响，但有利于进一步完善 公司知识产权保护体系，充分发挥自主知识产权优势，促进技术创新，形成持续 创新机制，提升公司的综合竞争力。敬请广大投资者注意投资风险。 备查文件 1、国家知识产权局颁发的发明专利证书。 特此公告 证券代码：000931 证券简称：中关村 公告编号：2025-140 北京中关村科技发展（控股）股份有限公司 关于下属公司北京华素取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属 公司北京华素制药股份有限公司取得国家知识产权局颁发的发明专利证书，具体 情况如下： | 发明名称 | | | 专利申请日 | | 授权公告日 | | | 授权公告号 | 专利权人 | | | 专利号 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | - ...

Core Viewpoint - Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Zhongguancun, has received the Acceptance Notification from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets (specifications: 5mg, 10mg) [1] Group 1 - Buprenorphine is the first non-benzodiazepine anxiolytic drug [1] - In China, a total of four companies, including Beijing Huasu, have approved generic drugs for market entry, with two companies having passed the consistency evaluation for quality and efficacy of generic drugs [1]

Core Insights - The opening of the East District of Zhongguancun Dairong City marks a significant addition to high-quality consumption venues in the Zhongguancun area, featuring over 60 flagship stores and a park-style commercial layout to enhance consumer experiences [1] - The "2025 Beijing Consumption Season • Joyful Haidian" promotional activities aim to stimulate consumer spending through various discounts and unique events, contributing to the development of Beijing as an international consumption center [1] Group 1 - The East District of Zhongguancun Dairong City has introduced over 60 first stores, including 11 Beijing first stores, 26 western Beijing first stores, and 24 Haidian first stores, showcasing numerous international trendy brands and popular dining options [1] - The promotional activities include over 60 discount initiatives across more than 20 key shopping malls, featuring various forms such as discount promotions and point redemption [1] - Upcoming events during the New Year and Spring Festival will include countdowns and themed parties to create a festive shopping atmosphere [1] Group 2 - The "Cultural Season of Book Fragrance and Warm Winter" focuses on the integration of culture, commerce, tourism, and sports, launching projects like industrial tourism at Xiaomi Technology Park and VR digital experiences [2] - During the 14th Five-Year Plan period, Haidian District has added over 1.2 million square meters of commercial space and introduced 401 first stores, enhancing the local consumption capacity [2] - Future plans for Haidian District include optimizing consumer supply, deepening the integration of commerce and culture, and fostering new consumption scenarios involving artificial intelligence [2]

Core Viewpoint - The event held in Guangzhou on December 17 aimed to promote trade and economic cooperation between Inner Mongolia and international markets, showcasing Inner Mongolia's industrial clusters and development opportunities [1][3]. Group 1: Event Overview - The trade and economic negotiation event was organized by the China Council for the Promotion of International Trade and the Inner Mongolia government, with participation from representatives of various countries including the USA, Singapore, Spain, and others [1]. - The event gathered hundreds of political and business representatives to discuss collaboration and opportunities for open trade [1][3]. Group 2: Strategic Agreements - A tripartite agreement was signed between the Global M&A Fund, Zhongguancun Development Investment Co., and Inner Mongolia Tianyi International Cultural Trade Group to establish a long-term strategic partnership focused on industrial collaboration between Guangdong-Hong Kong-Macao Greater Bay Area and Inner Mongolia [4][6]. - The agreement aims to create a "Guangdong-Mongolia Industrial Collaborative Innovation Center" to attract enterprises from the Greater Bay Area to set up regional headquarters and R&D centers in Inner Mongolia [6]. Group 3: Empowering Local Enterprises - Regular events such as "Inner Mongolia Quality Products Promotion Conference" and "Supply Chain Matching Meetings" will be organized to connect Inner Mongolia enterprises with buyers and large corporations in the Greater Bay Area [7]. - The collaboration will provide comprehensive capital services for high-quality Inner Mongolia enterprises planning financing, mergers, or listings [7]. Group 4: Innovation and Productivity - The partnership will facilitate the establishment of "Guangdong-Mongolia Collaborative Innovation Industrial Parks" to support the production and regional business of Greater Bay Area enterprises in Inner Mongolia [8]. - A "New Quality Productivity Empowerment Plan" will be implemented to enhance the technological innovation capabilities and market competitiveness of local enterprises through expert consultations and training [8]. Group 5: Investment Fund Initiatives - The three parties are exploring the establishment of a market-oriented investment fund focused on "Guangdong-Mongolia Industrial Collaboration," targeting high-growth local enterprises in Inner Mongolia and modern service projects [9]. Group 6: Support for Cultural and Tourism Industries - The Global M&A Fund's chairman emphasized the importance of capital and mechanisms in commercializing and internationalizing Inner Mongolia's cultural and tourism resources, aligning with the "14th Five-Year Plan" to develop new quality productivity [11]. - The use of Real Data Assets (RDA) through blockchain technology is proposed to transform resources into marketable assets, providing new financing pathways for cultural tourism projects [13]. Group 7: Broader Collaborative Actions - Three major collaborative actions were proposed, including an "Asset Going Global Plan" to connect Inner Mongolia's quality cultural tourism projects with global capital, a "Platform Co-construction Action" to establish a promotion center in Hong Kong, and a "Fund Interaction Action" to support the upgrade and internationalization of Inner Mongolia's cultural tourism and agricultural industries [15].

本公司的主要业务为向客户提供融资租赁及咨询服务。订立融资租赁协议为本公司部分日常及一般业 务，预期将为本公司带来稳定收入及现金流。 中关村科技租赁(01601)发布公告，于2025年12月18日，本公司作为出租人与承租人精进电动科技(菏泽) 有限公司订立融资租赁协议II，据此，(i)出租人将购入承租人自有租赁资产II，转让价款为人民币4900 万元;及(ii)出租人将租赁资产II租回给承租人，租赁期为24个月，总租赁款项约为人民币5235.18万元， 包括融资租赁本金为人民币4900万元及融资租赁利息收入(含增值税)约为人民币335.18万元。 租赁资产II为生产加工机床等设备，账面净值约为人民币5108.67万元。 ...